

# Call 13 Indicative topics

**Hugh Lavery**  
**18 October 2017, Brussels**

# Call 13 indicative topics

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

[iwona.jablonska@imi.europa.eu](mailto:iwona.jablonska@imi.europa.eu)

- Genome-environment interactions in inflammatory skin disease

[iwona.jablonska@imi.europa.eu](mailto:iwona.jablonska@imi.europa.eu)

- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

[iwona.jablonska@imi.europa.eu](mailto:iwona.jablonska@imi.europa.eu)

# Call 13 indicative topics

- Support and coordination action for the projects of the neurodegeneration area of the innovative medicines initiative  
[elisabetta.vaudano@imi.europa.eu](mailto:elisabetta.vaudano@imi.europa.eu)
- Mitochondrial dysfunction in neurodegeneration  
[elisabetta.vaudano@imi.europa.eu](mailto:elisabetta.vaudano@imi.europa.eu)
- Human tumour microenvironment immunoprofiling  
[oussama.karroum@imi.europa.eu](mailto:oussama.karroum@imi.europa.eu)
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use  
[angela.wittelsberger@imi.europa.eu](mailto:angela.wittelsberger@imi.europa.eu)

# Call 13 indicative topics

- CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now  
[nathalie.seigneuret@imi.europa.eu](mailto:nathalie.seigneuret@imi.europa.eu)
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice  
[nathalie.seigneuret@imi.europa.eu](mailto:nathalie.seigneuret@imi.europa.eu)
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease  
[isabella.tamagnini@imi.europa.eu](mailto:isabella.tamagnini@imi.europa.eu)
- A sustainable European induced pluripotent stem cell platform  
[isabella.tamagnini@imi.europa.eu](mailto:isabella.tamagnini@imi.europa.eu)

# Call 13 indicative topics

- Federated and privacy-preserving machine learning in support of drug discovery [colm.carroll@imi.europa.eu](mailto:colm.carroll@imi.europa.eu)

- Pilot programme on a clinical compound bank for repurposing

This programme includes the following topics:

- ❖ Cardiovascular diseases and diabetes
- ❖ Respiratory diseases
- ❖ Neurodegenerative diseases
- ❖ Rare/orphan disease

[salome.koussoroplis@imi.europa.eu](mailto:salome.koussoroplis@imi.europa.eu)

# Key information

## Indicative Call launch date?

Late November 2017

## Indicative Submission date?

Late Feb/early March 2018

## Webinars

Around the time of the Call launch – late November/early December

## Where to find information

[www.imi.europa.eu](http://www.imi.europa.eu)

Twitter: @IMI\_JU

LinkedIn (Innovative Medicines Initiative group)

IMI newsletter (sign up via IMI website)

# Finding project partners

- Start early
- Be proactive and be prepared to invest time and energy
- Where to look for partners
  - Use your contacts
  - Network at events
  - Use online partner search tools
    - The [Horizon 2020 Partner Search](#) tool on the Participant Portal.
    - CORDIS also offers a [partner search tool](#).
    - The German representative on the IMI States Representatives Group has a dedicated [partner search platform](#) for IMI Calls for proposals.
    - [Fit for Health 2.0](#) offers a [matchmaking portal](#).
  - Use social media